Miron Lila

Head of Corporate Development and Investor Relations Caidya

Miron Lila has over 15 years of healthcare-focused corporate finance, capital markets and M&A experience. He is currently Head of Corporate Development and Investor Relations at Caidya, where he is responsible for key corporate finance and strategic initiatives such as financings and M&A, overseeing investor relations as well as the Treasury and Reporting aspects of Finance. Formed through the merger of dMed and Clinipace, Caidya is a global clinical research organization (CRO) with full-service capabilities and a strategic footprint in 23 countries and regions, providing biopharma innovators with access to patient populations across the Americas, Europe and Asia Pacific.

Prior to Caidya, Miron was a senior healthcare investment banker and Asia franchise head at Citi, with 13 years of international investment banking experience in London and Hong Kong. During his time as a banker, Miron Lila successfully completed over 30 healthcare and biopharma transactions with US$ 15 billion in aggregate deal value, while also building a broad spectrum of senior-level corporate, investor and advisor relationships with unique geographic scope: Asia Pacific (Greater China, Korea, and Southeast Asia), Europe and the US.

Miron Lila holds a BSc degree from the London School of Economics and Political Science. Based in Hong Kong, Miron Lila is also a member of The Listing Committee of the Stock Exchange of Hong Kong, an independent administrative decision maker and an advisory body for the Exchange.